Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Down 57.6% in March

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 32,500 shares, a decline of 57.6% from the March 15th total of 76,600 shares. Based on an average trading volume of 447,500 shares, the short-interest ratio is currently 0.1 days.

Ono Pharmaceutical Stock Up 4.8 %

OTCMKTS:OPHLY traded up $0.19 during trading hours on Friday, hitting $4.15. The stock had a trading volume of 166,344 shares, compared to its average volume of 427,249. Ono Pharmaceutical has a 1-year low of $3.21 and a 1-year high of $5.20. The business has a 50 day simple moving average of $3.64 and a two-hundred day simple moving average of $3.74.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.